Shareholders Equity: The sum of preferred and common equity items.
MoonLake Immunotherapeutics (MLTX) had Shareholders Equity of $428.19M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-61.80M |
|
-- |
|
-- |
|
$61.66M |
|
$-61.66M |
|
$-0.06M |
|
$-61.72M |
|
$-61.72M |
|
$-61.80M |
|
$-61.80M |
|
$-61.80M |
|
$-61.80M |
|
$-61.66M |
|
$-60.76M |
|
73.92M |
|
73.92M |
|
$-0.84 |
|
$-0.84 |
|
| Balance Sheet Financials | |
$570.04M |
|
$0.49M |
|
$3.91M |
|
$573.95M |
|
$45.39M |
|
$99.51M |
|
$100.36M |
|
$145.75M |
|
$428.19M |
|
$428.19M |
|
|
Shareholders Equity |
$428.19M |
83.61M |
|
| Cash Flow Statement Financials | |
$-121.84M |
|
$0.42M |
|
$265.27M |
|
$334.52M |
|
$477.90M |
|
$143.39M |
|
$15.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.56 |
|
-- |
|
-- |
|
0.19 |
|
0.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-121.84M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.43% |
|
-14.43% |
|
-10.77% |
|
-11.71% |
|
$5.12 |
|
$-1.65 |
|
$-1.65 |
|